Form D · Pharmaceuticals
KALA BIO, Inc.
Arlington, MA · CIK 0001479419
Offering snapshot reported Mar 17, 2026 · SEC filing
- Reported sold
- $1.75M Offering amount: $1.75M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $1.75M Reported outside-investor minimum
- First sale
- Mar 3, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 17, 2026 | Initial | $1,753,500 | No comparison | 1 | SEC filing |
| Feb 13, 2026 | Initial | $2,250,600 | No comparison | 20 | SEC filing |
| Dec 31, 2024 | Initial | $10,749,667 | No comparison | 6 | SEC filing |
| Jun 28, 2024 | Initial | $12,499,192 | No comparison | 5 | SEC filing |
| Nov 29, 2021 | Initial | $16,122,541 | No comparison | 26 | SEC filing |
| Apr 13, 2016 | Initial | $67,921,796 | No comparison | 25 | SEC filing |
| Aug 19, 2015 | Initial | $6,999,999 | No comparison | 1 | SEC filing |
| Apr 24, 2014 | Initial | $22,500,000 | No comparison | 16 | SEC filing |
| Feb 28, 2013 | Initial | $5,750,059 | No comparison | 10 | SEC filing |
| Mar 14, 2012 | Initial | $7,243,205 | No comparison | 10 | SEC filing |
| Nov 10, 2010 | Initial | $3,000,000 | No comparison | 9 | SEC filing |
| Dec 23, 2009 | Initial | $2,000,001 | No comparison | 10 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-576813
The total offering amount is based off the closing price of KALA BIO, Inc.'s common stock on March 3, 2026 ($0.3507) for 5 million shares of common stock being issued.
Source: Form D, filed Mar 17, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Todd Bazemore | Executive |
| Chaim Berger | Director |
| Kevin Bitterman | Director |
| Mark S. Blumenkranz | Director |
| Kim Brazzell | Executive |
| Hongming Chen | Executive |
| Yonatan Colman | Director |
| Peter Courossi | Executive |
| Marjan Farid | Director |
| Andrea Franz | Executive |
| Bernard Gilly | Director |
| Greg Grunberg | Director |
| Gregory Grunberg | Director |
| Justin Hanes | Director |
| Mark Iwicki | Director, Executive |
| Darius Kharabi | Executive |
| Andrew I. Koven | Director |
| Robert Langer | Director |
| David Lazar | Director |
| Charles Mc Dermott | Executive |
| Avi Minkowitz | Director, Executive |
| C. Daniel Myers | Director |
| Robert Paull | Director |
| Gregory D. Perry | Director |
| Guillaume Pfefer | Director, Executive |
| Kevin Pojasek | Executive |
| Hillel Posen | Director |
| Brendan Purdy | Director |
| Mary Reumuth | Executive |
| Howard B. Rosen | Director |
| Rajeev Shah | Director |
| Robert Tepper | Director |
| Eric L. Trachtenberg | Executive |
| Karen Wagner | Director |
| Chen Yu | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
1167 Massachusetts Avenue
Arlington, MA, 02476
Phone: 781-996-5252
Arlington, MA, 02476
Phone: 781-996-5252